Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Pain and Therapy
Published in: Pain and Therapy 1/2017

Open Access 01-06-2017 | Review

The Basic Pharmacology of Opioids Informs the Opioid Discourse about Misuse and Abuse: A Review

Authors: Joseph V. Pergolizzi Jr., Jo Ann LeQuang, Garrett K. Berger, Robert B. Raffa

Published in: Pain and Therapy | Issue 1/2017

Login to get access

Abstract

Morphine and other opioids are widely used to manage moderate to severe acute pain syndromes, such as pain associated with trauma or postoperative pain, and they have been used to manage chronic pain, even chronic nonmalignant pain. However, recent years have seen a renewed recognition of the potential for overuse, misuse, and abuse of opioids. Therefore, prescribing opioids is challenging for healthcare providers in that clinical effectiveness must be balanced against negative outcomes—with the possibility that neither are achieved perfectly. The current discourse about the dual ‘epidemics’ of under-treatment of legitimate pain and the over-prescription of opioids is clouded by inadequate or inaccurate understanding of opioid drugs and the endogenous pain pathways with which they interact. An understanding of the basic pharmacology of opioids helps inform the clinician and other stakeholders about these simultaneously under- and over-used agents.
Literature
1.
Manchikanti L, Helm S 2nd, Fellows B, et al. Opioid epidemic in the United States. Pain Physician. 2012;15[3 Suppl]:ES9–38.PubMed
2.
Rudd RA, Aleshire N, Zibbell JE, Gladden RM. Increases in drug and opioid overdose deaths-United States, 2000–2014. MMWR Morb Mortal Wkly Rep. 2016;64(50–51):1378–82.PubMedCrossRef
3.
4.
Jones CM. Heroin use and heroin use risk behaviors among nonmedical users of prescription opioid pain relievers—United States, 2002–2004 and 2008–2010. Drug Alcohol Depend. 2013;132(1–2):95–100.PubMedCrossRef
5.
Karakula SL, Weiss RD, Griffin ML, Borges AM, Bailey AJ, McHugh RK. Delay discounting in opioid use disorder: differences between heroin and prescription opioid users. Drug Alcohol Depend. 2016;169:68–72.PubMedCrossRef
6.
Florence CS, Zhou C, Luo F, Xu L. The economic burden of prescription opioid overdose, abuse, and dependence in the United States, 2013. Med Care. 2016;54(10):901–6.PubMedCrossRef
7.
Manchikanti L, Boswell MV, Hirsch JA. Lessons learned in the abuse of pain-relief medication: a focus on healthcare costs. Expert Rev Neurother. 2013;13(5):527–43 (quiz 544).PubMedCrossRef
8.
9.
10.
Beaudoin FL, Banerjee GN, Mello MJ. State-level and system-level opioid prescribing policies: the impact on provider practices and overdose deaths, a systematic review. J Opioid Manag. 2016;12(2):109–18.PubMed
11.
Cleary J, Simha N, Panieri A, et al. Formulary availability and regulatory barriers to accessibility of opioids for cancer pain in India: a report from the Global Opioid Policy Initiative (GOPI). Ann Oncol ESMO. 2013;24[Suppl 11]:xi33–40.CrossRef
12.
Cleary J, De Lima L, Eisenchlas J, Radbruch L, Torode J, Cherny NI. Formulary availability and regulatory barriers to accessibility of opioids for cancer pain in Latin America and the Caribbean: a report from the Global Opioid Policy Initiative (GOPI). Ann Oncol ESMO. 2013;24[Suppl 11]:xi41–50.CrossRef
13.
Cleary J, Powell RA, Munene G, et al. Formulary availability and regulatory barriers to accessibility of opioids for cancer pain in Africa: a report from the Global Opioid Policy Initiative (GOPI). Ann Oncol ESMO. 2013;24[Suppl 11]:xi14–23.CrossRef
14.
Cleary J, Silbermann M, Scholten W, Radbruch L, Torode J, Cherny NI. Formulary availability and regulatory barriers to accessibility of opioids for cancer pain in the Middle East: a report from the Global Opioid Policy Initiative (GOPI). Ann Oncol ESMO. 2013;24[Suppl 11]:xi51–9.CrossRef
15.
Cleary J, Radbruch L, Torode J, Cherny NI. Formulary availability and regulatory barriers to accessibility of opioids for cancer pain in Asia: a report from the Global Opioid Policy Initiative (GOPI). Ann Oncol ESMO. 2013;24[Suppl 11]:xi24–32.CrossRef
16.
17.
Daher M. Pain relief is a human right. Asian Pac J Cancer Prev. 2010;11[Suppl 1]:97–101.PubMed
18.
International Pain Summit of the International Association for the Study of Pain. Declaration of Montreal: declaration that access to pain management is a fundamental human right. J Pain Palliat Care Pharmacother. 2011;25(1):29–31.PubMedCrossRef
19.
20.
Fornasari D. Pain mechanisms in patients with chronic pain. Clin Drug Investig. 2012;32[Suppl 1]:45–52.CrossRef
21.
22.
23.
Zhang M, Wang X, Zhang D, et al. Orphanin FQ antagonizes the inhibition of Ca(2+) currents induced by mu-opioid receptors. J Mol Neurosci. 2005;25(1):21–7.PubMedCrossRef
24.
Thompson GL, Lane JR, Coudrat T, Sexton PM, Christopoulos A, Canals M. Biased agonism of endogenous opioid peptides at the mu-opioid receptor. Mol Pharmacol. 2015;88(2):335–46.PubMedCrossRef
25.
Bannister K, Dickenson AH. What do monoamines do in pain modulation? Curr Opin Support Palliat Care. 2016;10(2):143–8.PubMedCrossRef
26.
Blier P. Crosstalk between the norepinephrine and serotonin systems and its role in the antidepressant response. J Psychiatry Neurosci. 2001;26[Suppl]:S3–10.PubMedPubMedCentral
27.
Pergolizzi JV Jr, Raffa RB, Taylor R Jr. Treating acute pain in light of the chronification of pain. Pain Manag Nurs. 2014;15(1):380–90.PubMedCrossRef
28.
29.
Joo DT. Mechanisms of opioid tolerance: merging evidence and therapeutic implications. Can J Anaesth. 2007;54(12):969–76.PubMedCrossRef
30.
31.
Lynch ME. Antidepressants as analgesics: a review of randomized controlled trials. J Psychiatry Neurosci. 2001;26(1):30–6.PubMedPubMedCentral
32.
Mercer SL, Coop A. Opioid analgesics and P-glycoprotein efflux transporters: a potential systems-level contribution to analgesic tolerance. Curr Top Med Chem. 2011;11(9):1157–64.PubMedPubMedCentralCrossRef
33.
Lalovic B, Kharasch E, Hoffer C, Risler L, Liu-Chen LY, Shen DD. Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites. Clin Pharmacol Ther. 2006;79(5):461–79.PubMedCrossRef
34.
Okura T, Hattori A, Takano Y, et al. Involvement of the pyrilamine transporter, a putative organic cation transporter, in blood–brain barrier transport of oxycodone. Drug Metab Dispos. 2008;36(10):2005–13.PubMedCrossRef
35.
Raffa RB, Clark-Vetri R, Tallarida RJ, Wertheimer AI. Combination strategies for pain management. Expert Opin Pharmacother. 2003;4(10):1697–708.PubMedCrossRef
36.
Kenakin T, Christopoulos A. Signalling bias in new drug discovery: detection, quantification and therapeutic impact. Nat Rev Drug Discov. 2013;12(3):205–16.PubMedCrossRef
37.
Raffa RB, Budd K. Buprenorphine—the unique opioid analgesic. Stuttgart: Georg Thieme Verlag; 2005.
38.
Pergolizzi J, Aloisi AM, Dahan A, et al. Current knowledge of buprenorphine and its unique pharmacological profile. Pain Pract. 2010;10(5):428–50.PubMedCrossRef
39.
40.
Cowan A. Buprenorphine: new pharmacological aspects. Int J Clin Pract Suppl. 2003;133:3–8 (discussion 23-24).
41.
Cicero TJ, Ellis MS, Surratt HL, Kurtz SP. Factors contributing to the rise of buprenorphine misuse: 2008–2013. Drug Alcohol Depend. 2014;142:98–104.PubMedCrossRef
42.
Canadian Agency for Drugs and Technologies in Health. Suboxone versus methadone for the treatment of opioid dependence: a review of the clinical and cost-effectiveness. Ottawa: Canadian Agency for Drugs and Technologies in Health. 2013.
43.
44.
Nakajima K, Obata H, Iriuchijima N, Saito S. An increase in spinal cord noradrenaline is a major contributor to the antihyperalgesic effect of antidepressants after peripheral nerve injury in the rat. Pain. 2012;153(5):990–7.PubMedCrossRef
45.
Stein C. The control of pain in peripheral tissue by opioids. N Engl J Med. 1995;332(25):1685–90.PubMedCrossRef
46.
Raffa RB, Friderichs E, Reimann W, et al. Complementary and synergistic antinociceptive interaction between the enantiomers of tramadol. J Pharmacol Exp Ther. 1993;267(1):331–40.PubMed
47.
Raffa RB. Basic pharmacology relevant to drug abuse assessment: tramadol as example. J Clin Pharm Ther. 2008;33(2):101–8.PubMedCrossRef
48.
Raffa RB, Buschmann H, Christoph T, et al. Mechanistic and functional differentiation of tapentadol and tramadol. Expert Opin Pharmacother. 2012;13(10):1437–49.PubMedCrossRef
49.
Schroder W, Tzschentke TM, Terlinden R, et al. Synergistic interaction between the two mechanisms of action of tapentadol in analgesia. J Pharmacol Exp Ther. 2011;337(1):312–20.PubMedPubMedCentralCrossRef
50.
Kress HG. Tapentadol and its two mechanisms of action: is there a new pharmacological class of centrally-acting analgesics on the horizon? Eur J Pain. 2010;14(8):781–3.PubMedCrossRef
51.
Linz K, Christoph T, Tzschentke TM, et al. Cebranopadol: a novel potent analgesic nociceptin/orphanin FQ peptide and opioid receptor agonist. J Pharmacol Exp Ther. 2014;349(3):535–48.PubMedCrossRef
52.
Raffa RB, Pergolizzi JV Jr. A modern analgesics pain ‘pyramid’. J Clin Pharm Ther. 2014;39(1):4–6.PubMedCrossRef
53.
Marinangeli F, Ciccozzi A, Leonardis M, et al. Use of strong opioids in advanced cancer pain: a randomized trial. J Pain Symptom Manag. 2004;27(5):409–16.CrossRef
54.
Foster A, Mobley E, Wang Z. Complicated pain management in a CYP450 2D6 poor metabolizer. Pain Pract. 2007;7(4):352–6.PubMedCrossRef
55.
Haufroid V, Hantson P. CYP2D6 genetic polymorphisms and their relevance for poisoning due to amfetamines, opioid analgesics and antidepressants. Clin Toxicol (Phila). 2015;53(6):501–10.CrossRef
56.
Mikus G, Somogyi AA, Bochner F, Chen ZR. Polymorphic metabolism of opioid narcotic drugs: possible clinical implications. Ann Acad Med Singap. 1991;20(1):9–12.PubMed
57.
58.
59.
Caraceni A. The EPCRC project to revise the European Association for Palliative Care (EAPC) guidelines on the use of opioids for cancer pain. Palliat Med. 2011;25(5):389–90.PubMedCrossRef
60.
Caraceni A, Davies A, Poulain P, Cortes-Funes H, Panchal SJ, Fanelli G. Guidelines for the management of breakthrough pain in patients with cancer. J Natl Compr Cancer Netw. 2013;11[Suppl 1]:S29–36.CrossRef
61.
Caraceni A, De Conno F, Kaasa S, Radbruch L, Hanks G. Update on cancer pain guidelines. J Pain Symptom Manag. 2009;38(3):e1–3.CrossRef
62.
Chou R. 2009 Clinical guidelines from the American Pain Society and the American Academy of Pain Medicine on the use of chronic opioid therapy in chronic noncancer pain: what are the key messages for clinical practice? Pol Arch Med Wewn. 2009;119(7–8):469–77.PubMed
63.
Ansari H, Kouti L. Drug interaction and serotonin toxicity with opioid use: another reason to avoid opioids in headache and migraine treatment. Curr Pain Headache Rep. 2016;20(8):50.PubMedCrossRef
64.
Stein C, Baerwald C. Opioids for the treatment of arthritis pain. Expert Opin Pharmacother. 2014;15(2):193–202.PubMedCrossRef
65.
66.
Cheatle MD, O’Brien CP. Opioid therapy in patients with chronic noncancer pain: diagnostic and clinical challenges. Adv Psychosom Med. 2011;30:61–91.PubMedCrossRef
67.
Stein C, Reinecke H, Sorgatz H. Opioid use in chronic noncancer pain: guidelines revisited. Curr Opin Anaesthesiol. 2010;23(5):598–601.PubMedCrossRef
68.
Zhang W, Doherty M, Arden N, et al. EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2005;64(5):669–81.PubMedCrossRef
69.
Zhang W, Doherty M, Bardin T, et al. EULAR evidence based recommendations for gout. Part II: management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2006;65(10):1312–24.PubMedPubMedCentralCrossRef
70.
Zhang W, Doherty M, Leeb BF, et al. EULAR evidence based recommendations for the management of hand osteoarthritis: report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2007;66(3):377–88.PubMedCrossRef
71.
Zhang W, Moskowitz RW, Nuki G, et al. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthr Cartil. 2008;16(2):137–62.PubMedCrossRef
72.
73.
74.
Bell K, Salmon A. Pain, physical dependence and pseudoaddiction: redefining addiction for ‘nice’ people? Int J Drug Policy. 2009;20(2):170–8.PubMedCrossRef
75.
Miyoshi H, Leckband S. Bonica’s management of pain. Philadelphia: Lippincott Williams & Wilkins; 2001.
76.
Kirsh KL, Whitcomb LA, Donaghy K, Passik SD. Abuse and addiction issues in medically ill patients with pain: attempts at clarification of terms and empirical study. Clin J Pain. 2002;18[4 Suppl]:S52–60.PubMedCrossRef
77.
Cepeda-Benito A, Davis K, Harraid J. Associative and behavioral tolerance to the analgesic effects of nicotine in rats: tail flick and paw-lick assays. Psychopharmacology. 2005;180:224–33.PubMedCrossRef
78.
Manchikanti L, Abdi S, Atluri S, et al. American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: Part 2-guidance. Pain Physician. 2012;15[3 Suppl]:S67–116.PubMed
79.
Smith HS, Smith JM, Seidner P. Opioid-induced nausea and vomiting. Ann Palliat Med. 2012;1(2):121–9.PubMed
80.
Laugsand E, Fladvad T, Skorpen F, et al. Clinical and genetic factors associated with nausea and vomiting in cancer patients receiving opioids. Eur J Cancer Care. 2011;47:1682–91.CrossRef
81.
Pergolizzi JV Jr, Philip BK, Leslie JB, Taylor R Jr, Raffa RB. Perspectives on transdermal scopolamine for the treatment of postoperative nausea and vomiting. J Clin Anesth. 2012;24(4):334–45.PubMedCrossRef
82.
83.
Hermens J, Ebertz J, Hanifin J, Hirshman C. Comparison of histamine release in human skin mast cells induced by morphine, fentanyl, and oxymorphone. Anesthesiology. 1985;62(2):124–9.PubMedCrossRef
84.
85.
Ganesh A, Maxwell L. Pathophysiology and management of opioid-induced pruritus. Drugs. 2007;67(16):2323–33.PubMedCrossRef
86.
Bruera E, Miller M, Macmillan K, Kuehn N. Neuropsychological effects of methylphenidate in patients receiving a continuous infusion of narcotics for cancer pain. Pain. 1992;48(2):163–6.PubMedCrossRef
87.
Wilwerding MB, Loprinzi CL, Mailliard JA, et al. A randomized, crossover evaluation of methylphenidate in cancer patients receiving strong narcotics. Support Care Cancer. 1995;3(2):135–8.PubMedCrossRef
88.
Webster L, Andrews M, Stoddard G. Modafinil treatment of opioid-induced sedation. Pain Med. 2003;4(2):135–40.PubMedCrossRef
89.
Stone P, Minton O. European Palliative Care Research collaborative pain guidelines. Central side-effects management: what is the evidence to support best practice in the management of sedation, cognitive impairment and myoclonus? Palliat Med. 2011;25(5):431–41.PubMedCrossRef
90.
Nuckols TK, Anderson L, Popescu I, et al. Opioid prescribing: a systematic review and critical appraisal of guidelines for chronic pain. Ann Intern Med. 2014;160(1):38–47.PubMedCrossRef
91.
Neumar RW, Shuster M, Callaway CW, et al. Part 1: Executive summary: 2015 American Heart Association guidelines update for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation. 2015;132[18 Suppl 2]:S315–67.PubMedCrossRef
92.
93.
Al-Hasani R, Bruchas MR. Molecular mechanisms of opioid receptor-dependent signaling and behavior. Anesthesiology. 2011;115(6):1363–81.PubMedPubMedCentral
94.
Verhamme KM, Sturkenboom MC, Stricker BH, Bosch R. Drug-induced urinary retention: incidence, management and prevention. Drug Saf Drug Exp. 2008;31(5):373–88.CrossRef
95.
Marret E, Kurdi O, Zufferey P, Bonnet F. Effects of nonsteroidal antiinflammatory drugs on patient-controlled analgesia morphine side effects: meta-analysis of randomized controlled trials. Anesthesiology. 2005;102(6):1249–60.PubMedCrossRef
96.
97.
Bell TJ, Panchal SJ, Miaskowski C, Bolge SC, Milanova T, Williamson R. The prevalence, severity, and impact of opioid-induced bowel dysfunction: results of a US and European Patient Survey (PROBE 1). Pain Med. 2009;10(1):35–42.PubMedCrossRef
98.
Bell T, Annunziata K, Leslie JB. Opioid-induced constipation negatively impacts pain management, productivity, and health-related quality of life: findings from the National Health and Wellness Survey. J Opioid Manag. 2009;5(3):137–44.PubMed
99.
Hess B, Bernardi M, Klotz HP. Attitude of Swiss physicians towards opioid-induced constipation: a national survey. Eur J Intern Med. 2011;22(5):527–31.PubMedCrossRef
100.
Hjalte F, Berggren AC, Bergendahl H, Hjortsberg C. The direct and indirect costs of opioid-induced constipation. J Pain Symptom Manag. 2010;40(5):696–703.CrossRef
101.
102.
Wood JD, Galligan JJ. Function of opioids in the enteric nervous system. Neurogastroenterol Motil. 2004;16[Suppl 2]:17–28.PubMedCrossRef
103.
Tassinari D, Sartori S, Tamburini E, et al. Adverse effects of transdermal opiates treating moderate-severe cancer pain in comparison to long-acting morphine: a meta-analysis and systematic review of the literature. J Palliat Med. 2008;11(3):492–501.PubMedCrossRef
104.
Kokki M, Kuronen M, Naaranlahti T, et al. Opioid-induced bowel dysfunction in patients undergoing spine surgery: comparison of oxycodone and oxycodone-naloxone treatment. Adv Ther. 2017;34(1):236–51
105.
Viscusi ER, Grond S, Ding L, Danesi H, Jones JB, Sinatra RS. A comparison of opioid-related adverse events with fentanyl iontophoretic transdermal system versus morphine intravenous patient-controlled analgesia in acute postoperative pain. Pain Manag. 2016;6(1):19–24.PubMedCrossRef
106.
Pergolizzi JV Jr, Scholten W, Smith KJ, Leighton-Scott J, Willis JC, Henningfield JE. The unique role of transdermal buprenorphine in the global chronic pain epidemic. Acta Anaesthesiol Taiwan. 2015;53(2):71–6.PubMedCrossRef
107.
Tarumi Y, Wilson MP, Szafran O, Spooner GR. Randomized, double-blind, placebo-controlled trial of oral docusate in the management of constipation in hospice patients. J Pain Symptom Manag. 2013;45(1):2–13.CrossRef
108.
Anantharamu T, Sharma S, Gupta AK, Dahiya N, Singh Brashier DB, Sharma AK. Naloxegol: first oral peripherally acting mu opioid receptor antagonists for opioid-induced constipation. J Pharmacol Pharmacother. 2015;6(3):188–92.PubMedPubMedCentralCrossRef
109.
Li Z, Pergolizzi JV, Huttner RP, Zampogna G, Breve F, Raffa RB. Management of opioid-induced constipation in pregnancy: a concise review with emphasis on the PAMORAs. J Clin Pharm Ther. 2015;40(6):615–9.PubMedCrossRef
110.
Diego L, Atayee R, Helmons P, Hsiao G, von Gunten CF. Novel opioid antagonists for opioid-induced bowel dysfunction. Expert Opin Investig Drugs. 2011;20(8):1047–56.PubMedCrossRef
111.
112.
Davis M, Goforth HW, Gamier P. Oxycodone combined with opioid receptor antagonists: efficacy and safety. Expert Opin Drug Saf. 2013;12(3):389–402.PubMedCrossRef
113.
114.
Birthi P, Nagar VR, Nickerson R, Sloan PA. Hypogonadism associated with long-term opioid therapy: A systematic review. J Opioid Manag. 2015;11(3):255–78.PubMedCrossRef
115.
Colameco S, Coren J. Opioid-induced endocrinopathy. J Am Osteopath Assoc. 2009;109:20–5.PubMed
116.
Walsh SL, Nuzzo PA, Lofwall MR, Holtman JR Jr. The relative abuse liability of oral oxycodone, hydrocodone and hydromorphone assessed in prescription opioid abusers. Drug Alcohol Depend. 2008;98(3):191–202.PubMedPubMedCentralCrossRef
117.
Pergolizzi JV, Raffa RB, Pergolizzi JS, Taylor R. Non-analgesic effects of opioids: factors relevant to opioid abuse and abuse-deterrent formulations. Curr Pharm Des. 2012;18(37):6109–15.PubMedCrossRef
118.
Garland EL, Froeliger B, Zeidan F, Suveg K, Howard MO. The downward spiral of chronic pain, prescription opioid misuse, and addiction: cognitive, affective, and neuropsychopharmacologic pathways. Neurosci Biobehav Rev. 2013; 37(10). doi:10.​1016/​j.​neubiorev.​2013.​08.​006.
119.
Cheatle MD. Prescription opioid misuse, abuse, morbidity, and mortality: balancing effective pain management and safety. Pain Med. 2015;16[Suppl 1]:S3–8.PubMedCrossRef
120.
Pergolizzi JV Jr, Gharibo C, Passik S, et al. Dynamic risk factors in the misuse of opioid analgesics. J Psychosom Res. 2012;72(6):443–51.PubMedCrossRef
121.
Boscarino JA, Kirchner HL, Pitcavage JM, et al. Factors associated with opioid overdose: a 10-year retrospective study of patients in a large integrated health care system. Subst Abus Rehabil. 2016;7:131–41.CrossRef
122.
Dunn KE, Barrett FS, Yepez-Laubach C, et al. Opioid overdose experience, risk behaviors, and knowledge in drug users from a rural versus an urban setting. J Subst Abus Treat. 2016;71:1–7.CrossRef
123.
Peck KR, Ehrentraut JH, Anghelescu DL. Risk factors for opioid misuse in adolescents and young adults with focus on oncology setting. J Opioid Manag. 2016;12(3):205–16.PubMed
124.
Ihongbe TO, Masho SW. Prevalence, correlates and patterns of heroin use among young adults in the United States. Addict Behav. 2016;63:74–81.PubMedCrossRef
125.
Dale R, Edwards J, Ballantyne J. Opioid risk assessment in palliative medicine. J Commun Support Oncol. 2016;14(3):94–100.CrossRef
126.
127.
Katz N, Adams E, Benneyan J, et al. Foundations of opioid risk management. Clin J Pain. 2007;23:103–18.PubMedCrossRef
128.
129.
Chang YP, Compton P. Opioid misuse/abuse and quality persistent pain management in older adults. J Gerontol Nurs. 2016;42(12):21–30.PubMedCrossRef
130.
Kristjansson S, McCutcheon VV, Agrawal A, et al. The variance shared across forms of childhood trauma is strongly associated with liability for psychiatric and substance use disorders. Brain Behav. 2016;6(2):e00432.PubMedPubMedCentralCrossRef
131.
Peles E, Adelson M, Seligman Z, Bloch M, Potik D, Schreiber S. Psychiatric comorbidity differences between women with history of childhood sexual abuse who are methadone-maintained former opiate addicts and non-addicts. Psychiatry Res. 2014;219(1):191–7.PubMedCrossRef
132.
Massaly N, Moron JA, Al-Hasani R. A trigger for opioid misuse: chronic pain and stress dysregulate the mesolimbic pathway and kappa opioid system. Front Neurosci. 2016;10:480.PubMedPubMedCentralCrossRef
133.
Mitsi V, Zachariou V. Modulation of pain, nociception, and analgesia by the brain reward center. Neuroscience. 2016;338:81–92.PubMedCrossRef
134.
Navratilova E, Morimura K, Xie JY, Atcherley CW, Ossipov MH, Porreca F. Positive emotions and brain reward circuits in chronic pain. J Comp Neurol. 2016;524(8):1646–52.PubMedCrossRef
135.
Inagaki TK, Ray LA, Irwin MR, Way BM, Eisenberger NI. Opioids and social bonding: naltrexone reduces feelings of social connection. Soc Cogn Affect Neurosci. 2016;11(5):728–35.PubMedPubMedCentralCrossRef
136.
Setnik B, Roland CL, Pixton G, Webster L. Measurement of drug liking in abuse potential studies: a comparison of unipolar and bipolar visual analog scales. J Clin Pharmacol. 2016; 57(2):266–74.
137.
Pergolizzi JV Jr, LeQuang JA. Abuse-deterrent formulations of opioid analgesics. Pain Pract. 2014;14(3):204–6.PubMedCrossRef
138.
Ruan X. Sustained-release morphine sulfate with sequestered naltrexone for moderate to severe pain: a new opioid analgesic formulation and beyond. Expert Opin Pharmacother. 2011;12(7):999–1001.PubMedCrossRef
139.
Metadata
Title
The Basic Pharmacology of Opioids Informs the Opioid Discourse about Misuse and Abuse: A Review
Authors
Joseph V. Pergolizzi Jr.
Jo Ann LeQuang
Garrett K. Berger
Robert B. Raffa
Publication date
01-06-2017
Publisher
Springer Healthcare
Published in
Pain and Therapy / Issue 1/2017
Print ISSN: 2193-8237
Electronic ISSN: 2193-651X
DOI
https://doi.org/10.1007/s40122-017-0068-3

Other articles of this Issue 1/2017

Pain and Therapy 1/2017 Go to the issue

Original Research

Survey on German Palliative Care Specialists’ Experiences with Advance Directives

Commentary

Valuing Individuals’ Preferences and Health Choices of Physical Exercise

Original Research

Frequency of Shoulder Corticosteroid Injections for Pain and Stiffness After Shoulder Surgery and Their Potential to Enhance Outcomes with Physiotherapy: A Retrospective Study

Commentary

Why We should Assess Patients’ Expectations in Clinical Trials

Original Research

High Body Mass Index and Use of Fentanyl Iontophoretic Transdermal System in Postoperative Pain Management: Results of a Pooled Analysis of Six Phase 3/3B Trials

Commentary

Genetic Testing for Opioid Pain Management: A Primer

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits